183490 — Enzychem Lifesciences Income Statement
0.000.00%
Last trade - 00:00
- KR₩149bn
- KR₩19bn
- KR₩76bn
- 17
- 31
- 82
- 36
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 31,469 | 25,818 | 22,975 | 26,638 | 76,039 |
Cost of Revenue | |||||
Gross Profit | 2,664 | 1,820 | 287 | 2,416 | 4,348 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 47,871 | 45,445 | 44,147 | 45,999 | 90,428 |
Operating Profit | -16,403 | -19,626 | -21,172 | -19,361 | -14,389 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16,676 | -19,232 | -29,504 | -25,581 | -9,879 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16,879 | -17,507 | -27,865 | -25,093 | -9,403 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -16,879 | -17,507 | -27,865 | -25,093 | -9,326 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -16,444 | -17,443 | -26,923 | -24,934 | -9,326 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -275 | -276 | -528 | -278 | -109 |
Dividends per Share |